Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKesson
Johnson and Johnson
Baxter
Boehringer Ingelheim

Last Updated: May 26, 2022

DrugPatentWatch Database Updates: New Patent Additions


✉ Email this page to a colleague

« Back to Dashboard

DrugPatentWatch Database Updates: New Patent Additions

These are patents which have been reported by the FDA since the last major update; they are not yet in the main database.
Applicant Tradename Generic Name Dosage NDA Number Approval Date Type RLD Patent No. Product Substance Delist Requested Patent Expiration Date Submitted Usecode Patented / Exclusive Use
Nalpropion CONTRAVE bupropion hydrochloride; naltrexone hydrochloride TABLET, EXTENDED RELEASE 200063 001 Sep 10, 2014 RX Yes See Plans and Pricing See Plans and Pricing 2022-05-19 U-1583 FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
Gilead Sciences Inc VEKLURY remdesivir POWDER 214787 001 Oct 22, 2020 RX Yes See Plans and Pricing See Plans and Pricing 2020-11-12 U-2984 TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION
Gilead Sciences Inc VEKLURY remdesivir POWDER 214787 002 Oct 22, 2020 RX Yes See Plans and Pricing See Plans and Pricing 2020-11-12 U-2984 TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION
Gilead Sciences Inc VEKLURY remdesivir POWDER 214787 001 Oct 22, 2020 RX Yes See Plans and Pricing See Plans and Pricing 2020-11-12 U-3249 TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)
Gilead Sciences Inc VEKLURY remdesivir POWDER 214787 002 Oct 22, 2020 RX Yes See Plans and Pricing See Plans and Pricing 2020-11-12 U-3249 TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)
Gilead Sciences Inc VEKLURY remdesivir POWDER 214787 001 Oct 22, 2020 RX Yes See Plans and Pricing See Plans and Pricing 2020-11-12 U-3367 TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION
Gilead Sciences Inc VEKLURY remdesivir POWDER 214787 002 Oct 22, 2020 RX Yes See Plans and Pricing See Plans and Pricing 2020-11-12 U-3367 TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION
>Applicant >Tradename >Generic Name >Dosage >NDA >Number >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Requested >Patent Expiration >Usecode >Patented / Exclusive Use

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Colorcon
McKesson
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.